Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 6 of 6
Full-Text Articles in Medicine and Health Sciences
Combination Olanzapine And Samidorphan For The Management Of Schizophrenia And Bipolar 1 Disorder In Adults: A Narrative Review, Hannah W. Haddad, Elena Boardman, Brooke Williams, Rama Mouhaffel, Adam M. Kaye, Alan David Kaye
Combination Olanzapine And Samidorphan For The Management Of Schizophrenia And Bipolar 1 Disorder In Adults: A Narrative Review, Hannah W. Haddad, Elena Boardman, Brooke Williams, Rama Mouhaffel, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Schizophrenia is a debilitating psychotic disorder characterized by positive symptoms such as delusions, hallucinations, and disorganized thoughts, and negative symptoms like lack of effect or motivation. Bipolar 1 disorder (B1D) is a psychiatric illness characterized by recurrent manic episodes in alternation with depressive episodes and interspersed periods of euthymia, ultimately resulting in psychological distress and impairment of daily functioning. Effective treatments are needed for both schizophrenia and B1D to reach the treatment goals of reducing the debilitating symptomology, improving social functioning and quality of life, and increasing the chances of recovery and more favorable long-term outcomes. To date, olanzapine is …
Catatonia: Clinical Overview Of The Diagnosis, Treatment, And Clinical Challenges, Amber N. Edinoff, Sarah E. Kaufman, Janice W. Hollier, Celina G. Virgen, Christian A. Karam, Garett W. Malone, Elyse M. Cornett, Adam M. Kaye, Alan David Kaye
Catatonia: Clinical Overview Of The Diagnosis, Treatment, And Clinical Challenges, Amber N. Edinoff, Sarah E. Kaufman, Janice W. Hollier, Celina G. Virgen, Christian A. Karam, Garett W. Malone, Elyse M. Cornett, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Catatonia is a syndrome that has been associated with several mental illness disorders but that has also presented as a result of other medical conditions. Schizophrenia and other psychiatric disorders such as mania and depression are known to be associated with catatonia; however, several case reports have been published of certain medical conditions inducing catatonia, including hypo-natremia, cerebral venous sinus thrombosis, and liver transplantation. Neuroleptic Malignant Syndrome and anti-NMDA receptor encephalitis are also prominent causes of catatonia. Patients taking benzodiazepines or clozapine are also at risk of developing catatonia following the withdrawal of these medications—it is speculated that the prolonged …
Paliperidone 3-Month Injection For Treatment Of Schizophrenia: A Narrative Review, Amber N. Edinoff, Prithvi K. Doppalapudi, Claudia V. Orellana, Caroline Ochoa, Shelby J. Patti, Yahya A. Ghaffar, Elyse M. Cornett, Aaron J. Kaye, Omar Viswanath, Ivan Urits, Adam M. Kaye, Alan David Kaye
Paliperidone 3-Month Injection For Treatment Of Schizophrenia: A Narrative Review, Amber N. Edinoff, Prithvi K. Doppalapudi, Claudia V. Orellana, Caroline Ochoa, Shelby J. Patti, Yahya A. Ghaffar, Elyse M. Cornett, Aaron J. Kaye, Omar Viswanath, Ivan Urits, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Given the typical age onset of schizophrenia, there are tremendous economic and social impacts that extend beyond the person and their families. One critical determinant of the diseases' impact is the patient's adherence to antipsychotic drug treatment. Approved in 2015 for the treatment of schizophrenia, paliperidone palmitate (Invega Trinza, a 3-month injection, noted as PP3M) is a second-generation long-acting injectable antipsychotic medication. Among the different formulations offered for palmitate paliperidone, including the 1 and 3-month formulations, the longer duration 3-month formulation was better at preventing relapse in schizophrenic patients. To date, different formulations of palmitate paliperidone that have been studied …
Aripiprazole Lauroxil, A Novel Injectable Long-Acting Antipsychotic Treatment For Adults With Schizophrenia: A Comprehensive Review, Kunal Maini, Haley Gould, Jessica Hicks, Fatima Iqbal, James Patterson, Amber N. Edinoff, Elyse M. Cornett, Adam M. Kaye, Omar Viswanath, Ivan Urits, Alan David Kaye
Aripiprazole Lauroxil, A Novel Injectable Long-Acting Antipsychotic Treatment For Adults With Schizophrenia: A Comprehensive Review, Kunal Maini, Haley Gould, Jessica Hicks, Fatima Iqbal, James Patterson, Amber N. Edinoff, Elyse M. Cornett, Adam M. Kaye, Omar Viswanath, Ivan Urits, Alan David Kaye
School of Pharmacy Faculty Articles
Purpose of Review. This is a comprehensive review of the literature regarding the use of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health disorder that currently affects approximately 3.3 million people in the United States. Its symptoms, which must be present for more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, …
Selective Serotonin Reuptake Inhibitors And Clozapine: Clinically Relevant Interactions And Considerations, Amber N. Edinoff, Juliana M. Fort, Joshua J. Woo, Christopher D. Causey, Caroline R. Burroughs, Elyse M. Cornett, Adam M. Kaye, Alan David Kaye
Selective Serotonin Reuptake Inhibitors And Clozapine: Clinically Relevant Interactions And Considerations, Amber N. Edinoff, Juliana M. Fort, Joshua J. Woo, Christopher D. Causey, Caroline R. Burroughs, Elyse M. Cornett, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
The monoamine hypothesis of depression attributes the symptoms of major depressive disorders to imbalances of serotonin, noradrenaline, and dopamine in the limbic areas of the brain. The preferential targeting of serotonin receptor (SERT) by selective serotonin reuptake inhibitors (SSRIs) has offered an opportunity to reduce the range of these side effects and improve patient adherence to pharmacotherapy. Clozapine remains an effective drug against treatment-resistant schizophrenia, defined as failing treatment with at least two different antipsychotic medications. Patients with schizophrenia who display a constellation of negative symptoms respond poorly to antipsychotic monotherapy. Negative symptoms include the diminution of motivation, interest, or …
Lumateperone Tosylate, A Selective And Concurrent Modulator Of Serotonin, Dopamine, And Glutamate, In The Treatment Of Schizophrenia, Kunal Maini, Janice W. Hollier, Haley Gould, Victoria Bollich, John Laforge, Elyse M. Cornett, Amber N. Edinoff, Adam M. Kaye, Alan David Kaye
Lumateperone Tosylate, A Selective And Concurrent Modulator Of Serotonin, Dopamine, And Glutamate, In The Treatment Of Schizophrenia, Kunal Maini, Janice W. Hollier, Haley Gould, Victoria Bollich, John Laforge, Elyse M. Cornett, Amber N. Edinoff, Adam M. Kaye, Alan David Kaye
School of Pharmacy Faculty Articles
Purpose of Review This is a comprehensive review of the literature regarding the use of Lumateperone tosylate for schizophrenia. This review presents the background, evidence, and indications for the use of lumateperone tosylate in the treatment of schizophrenia. Recent Findings Schizophrenia is a chronic mental health disorder that affects approximately 3.3 million people in the United States. Its symptoms, which must be present more than six months, are comprised of disorganized behavior and speech, a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen by others, delusions, decreased social commitment, and decreased motivation. The majority of …